Profound Medical (TSE:PRN) has released an update.
Profound Medical’s TULSA procedure is gaining recognition as a versatile, non-invasive treatment for various stages of prostate disease, evidenced by 25 presentations at major medical conferences in 2024. The TULSA-PRO system, which offers a ‘one-and-done’ approach to ablate diseased tissue without incisions or radiation, has been backed by positive results from institutions like the Mayo Clinic. This growing clinical support positions TULSA as a potential mainstream option for prostate disease management.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
